ITMI992263A1 - FIBROLIPOPROTEIC COMPLEXES AND COMPOSITIONS CONTAINING THEM - Google Patents
FIBROLIPOPROTEIC COMPLEXES AND COMPOSITIONS CONTAINING THEM Download PDFInfo
- Publication number
- ITMI992263A1 ITMI992263A1 IT1999MI002263A ITMI992263A ITMI992263A1 IT MI992263 A1 ITMI992263 A1 IT MI992263A1 IT 1999MI002263 A IT1999MI002263 A IT 1999MI002263A IT MI992263 A ITMI992263 A IT MI992263A IT MI992263 A1 ITMI992263 A1 IT MI992263A1
- Authority
- IT
- Italy
- Prior art keywords
- complexes
- peptides
- fibrolipoprotein
- fibers
- derivatives
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000000835 fiber Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 235000013311 vegetables Nutrition 0.000 claims description 9
- 108010076119 Caseins Proteins 0.000 claims description 6
- 102000011632 Caseins Human genes 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- 229940021722 caseins Drugs 0.000 claims description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- -1 phospholipid compound Chemical class 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 108010067454 caseinomacropeptide Proteins 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 210000003022 colostrum Anatomy 0.000 claims description 2
- 235000021277 colostrum Nutrition 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000004026 insulin derivative Substances 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229920005610 lignin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- XRXTWSABNBANQL-UHFFFAOYSA-N 2-amino-3-[bis(2-chloropropyl)carbamoyloxy]propanoic acid Chemical compound CC(Cl)CN(CC(C)Cl)C(=O)OCC(N)C(O)=O XRXTWSABNBANQL-UHFFFAOYSA-N 0.000 claims 1
- 241000209763 Avena sativa Species 0.000 claims 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 235000019895 oat fiber Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Description
Descrizione dell'invenzione industriale avente per titolo: Description of the industrial invention entitled:
"COMPLESSI FIBROLIPOPROTEICI E COMPOSIZIONI CHE LI CONTENGONO" "FIBROLIPOPROTEIC COMPLEXES AND COMPOSITIONS THAT CONTAIN THEM"
La presente invenzione ha per oggetto complessi fibrolipoproteici costituiti da una o più frazioni di proteine o peptidi di origine animale e/o vegetale (e/o peptidi ottenuti per idrolisi delle stesse proteine e/o eventualmente per sintesi), unitamente a uno o più composti fosfolipidici ed a una o più specie di fibre vegetali e/o animali, nonché composizioni farmaceutiche, dietetiche, o alimenti funzionali contenenti tali complessi fibrolipoproteici . The present invention relates to fibrolipoprotein complexes consisting of one or more fractions of proteins or peptides of animal and / or vegetable origin (and / or peptides obtained by hydrolysis of the same proteins and / or possibly by synthesis), together with one or more compounds phospholipids and one or more species of vegetable and / or animal fibers, as well as pharmaceutical, dietary, or functional food compositions containing such fibrolipoprotein complexes.
Da tempo sono state studiate ed identificate nei cibi di uso comune, sia di origine animale sia vegetale, alcune specifiche proteine (e/o alcuni peptidi da esse derivati per idrolisi e/o alternativamente ottenuti per sintesi) in grado di promuovere diverse e benefiche attività nutrizionali e terapeutiche. For some time, some specific proteins (and / or some peptides derived from them by hydrolysis and / or alternatively obtained by synthesis) able to promote different and beneficial activities have been studied and identified in commonly used foods, both of animal and vegetable origin. nutritional and therapeutic.
Esempi non limitativi di questa classe di proteine e/o peptidi sono costituiti da: Non-limiting examples of this class of proteins and / or peptides consist of:
a) lattoferrina. una proteina isolabile dal latte e dotate di attività antiossidante, antiinfiammatoria, immunostimolante nonché in grado di promuovere la biodisponibilità del Ferro (C.C. Winterbourn et al., 1990, Biochem. Biophys. Acta, 1055. 179; B.E. Britigan et al., 1994, Advances in Experimental Medicine and Biology, 357. 143); a) lactoferrin. a protein that can be isolated from milk and has antioxidant, anti-inflammatory, immunostimulating activity as well as promoting the bioavailability of Iron (C.C. Winterbourn et al., 1990, Biochem. Biophys. Acta, 1055. 179; B.E. Britigan et al., 1994, Advances in Experimental Medicine and Biology, 357. 143);
b) casomorfine. piccoli peptidi di 4-10 amminoacidi isolati dalla caseina e dotati di attività oppioide. Questi peptidi si sono dimostrati in grado di modulare la motilità intestinale e di stimolare la sintesi di ormoni anabolizzanti (J.L. Manbois et al., 1989, Lait, 69, 245); b) casomorphins. small peptides of 4-10 amino acids isolated from casein and endowed with opioid activity. These peptides have been shown to be able to modulate intestinal motility and stimulate the synthesis of anabolic hormones (J.L. Manbois et al., 1989, Lait, 69, 245);
c) peptidi in grado di inibire l’enzima di conversione deH’angiotensina I e quindi dotati di attività antipertensiva. Tali peptidi sono stati isolati dalla proteina di latte, farina di grano e pesce (Y. Aryoshi, 1993, Trends in Food Science and Technology, 4, 139); c) peptides capable of inhibiting the angiotensin I conversion enzyme and therefore have antihypertensive activity. These peptides have been isolated from the protein of milk, wheat meal and fish (Y. Aryoshi, 1993, Trends in Food Science and Technology, 4, 139);
d) peptidi isolati dalle caseine e dotati di attività immunostimolante (A.M. d) peptides isolated from caseins and endowed with immunostimulating activity (A.M.
Fiat et al., 93, J. Dairy Sci., 76, 301); Fiat et al., 93, J. Dairy Sci., 76, 301);
e) glicomacropeptidi isolati dalle caseine e dotati di proprietà nutrizionali favorenti lo sviluppo dei batteri intestinali (lactobacilli, bifidus, etc.), di attività antivirale e di attività antitrombotica (M. Yvon et al., 1994, Reprod. Nutr. Dev., 34, 527; P. Jolles et al., 1991, Trends in Food Sci. and Technology, February issue, 42); e) glycomacropeptides isolated from caseins and endowed with nutritional properties favoring the development of intestinal bacteria (lactobacilli, bifidus, etc.), antiviral activity and antithrombotic activity (M. Yvon et al., 1994, Reprod. Nutr. Dev., 34, 527; P. Jolles et al., 1991, Trends in Food Sci. And Technology, February issue, 42);
f) caseinfosfopeptidi in grado di promuovere la biodisponibilità di Ca, Mg e Zn e di prevenire l'insorgere dell'osteoporosi (Y.S. Lee, 1980, Br. J. Nutr. 43, 457; R. Saio et al., 1991, Biochem. Biophys. Acta, 1077. 413); g) peptidi ad alto contenuto di glutammina ottenibili dalle proteine della farina di grano ed in grado di promuovere l'accumulo muscolare di glicogene negli atleti (M. Vamier, 1995, Am. J. Physiol., 269. 309); f) caseinphosphopeptides able to promote the bioavailability of Ca, Mg and Zn and to prevent the onset of osteoporosis (Y.S. Lee, 1980, Br. J. Nutr. 43, 457; R. Saio et al., 1991, Biochem . Biophys. Acta, 1077, 413); g) peptides with a high glutamine content obtainable from wheat flour proteins and able to promote the muscle accumulation of glycogen in athletes (M. Vamier, 1995, Am. J. Physiol., 269. 309);
h) frazioni peptidiche purificate da colostro fo da siero di lattei contenenti fattori di crescita quali le "insulin-like growth factors", in grado di stimolare l'anabolismo proteico (A. Mero et al., 1997, J. Appi. Physiol., 83 (4), 1144); h) peptide fractions purified from colostrum or whey containing growth factors such as "insulin-like growth factors", capable of stimulating protein anabolism (A. Mero et al., 1997, J. Appi. Physiol. , 83 (4), 1144);
i) peptidi derivati dal siero di latte e dotati di attività antiossidante (L.B. i) peptides derived from whey and with antioxidant activity (L.B.
Colbert et al., 1991, T.H. Food Sci., 56(5), 1248); Colbert et al., 1991, T.H. Food Sci., 56 (5), 1248);
l) glutatione. un tripeptide presente in diversissime specie di alimenti (od ottenibili per sintesi) ed in grado di promuovere un'efficace attività antiossidante; l) glutathione. a tripeptide present in very different food species (or obtainable by synthesis) and able to promote an effective antioxidant activity;
m) camosina. un dipeptide presente soprattutto nelle carni animali (od ottenibili per sintesi) anch'esso dotato di un'elevata attività antiossidante. m) camosina. a dipeptide present above all in animal meats (or obtainable by synthesis) also endowed with a high antioxidant activity.
Le benefiche attività nutrizionali e terapeutiche di queste proteine e peptidi sono però fortemente limitate dall'assunzione per via orale di questi principi attivi, dato che essi vengono per la più parte e velocemente inattivati dagli enzimi proteolitici dello stomaco e dell'intestino. La presente ricerca ha sorprendentemente dimostrato che la somministrazione per via orale dei complessi fibrolipoproteici contenenti una o più di queste componenti peptidiche o proteiche dotate di benefiche attività nutrizionali e terapeutiche unitamente ad almeno un composto fosfolipidico animale e/o vegetale e ad una o più specie di fibre vegetali e/o animali costituisce un efficace e ben tollerato integratore nutrizionale in grado di incrementare in maniera sorprendentemente elevata le benefiche attività nutrizionali e terapeutiche di per sé ascrivibili alle singole componenti peptidiche e/o proteiche utilizzate. The beneficial nutritional and therapeutic activities of these proteins and peptides are however severely limited by the oral intake of these active ingredients, since they are mostly and quickly inactivated by the proteolytic enzymes of the stomach and intestines. The present research has surprisingly shown that the oral administration of the fibrolipoprotein complexes containing one or more of these peptide or protein components endowed with beneficial nutritional and therapeutic activities together with at least one animal and / or vegetable phospholipid compound and with one or more species of vegetable and / or animal fibers constitutes an effective and well tolerated nutritional supplement capable of surprisingly increasing the beneficial nutritional and therapeutic activities per se attributable to the individual peptide and / or protein components used.
Preferibilmente la componente proteica o peptidica costituisce dall' 1 al 50% in peso dei. complessi fibrolipoproteici mentre le componenti fosfolipidiche unitamente alla frazione di fibre rappresentano dal 50 al 99% in peso di tali complessi. Preferably the protein or peptide component constitutes from 1 to 50% by weight of the. fibrolipoprotein complexes while the phospholipidic components together with the fiber fraction represent from 50 to 99% by weight of these complexes.
In quest'ultima frazione, infine, il rapporto tra i fosfolipidi e le fibre variano preferibilmente da 1 :1 a 1 :20 in peso. Finally, in the latter fraction, the ratio between the phospholipids and the fibers preferably varies from 1: 1 to 1: 20 by weight.
Esempi non limitativi di frazioni proteiche (e/o di peptidi ottenuti per idrolisi di queste stesse proteine e/o per sintesi) sono le preparazioni proteiche prevalentemente di origine vegetale e/o animale già prima elencate. Non-limiting examples of protein fractions (and / or of peptides obtained by hydrolysis of these same proteins and / or by synthesis) are the protein preparations mainly of vegetable and / or animal origin already listed above.
Esempi non limitativi di specie fosfolipidiche di origine animale e/o vegetale sono rappresentati dalla fosfatidilcolina, fosfatidiletanolammina, mono- e dimetilfosfatidiletanolammina, fosfatidilserina, fosfatidilinositolo e derivati, fosfatidilglicerolo, cardiolipine, lisofosfolipidi di detti composti e/o loro miscele. Non-limiting examples of phospholipid species of animal and / or vegetable origin are represented by phosphatidylcholine, phosphatidylethanolamine, mono- and dimethylphosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and derivatives, phosphatidylglycerol, cardiolipolipins, lysophos / mixtures and their mixtures.
Esempi non limitativi di fibre di origine vegetale e/o animale sono rappresentati da: fibre di avena, pomodoro, guar, patata, specie diverse di cellulose, chitine e chitosani, pectine, insuline, fructooligosaccaridi, lignine e derivati, ciclodestrine e derivati, amidi di varia origine e loro miscele. Non-limiting examples of fibers of vegetable and / or animal origin are represented by: fibers from oats, tomatoes, guar, potatoes, various species of cellulose, chitins and chitosans, pectins, insulins, fructooligosaccharides, lignins and derivatives, cyclodextrins and derivatives, starches of various origins and their mixtures.
La presente invenzione riguarda inoltre le diverse specie di composizioni galeniche (compresse, confetti, caramelle, bustine, cialde effervescenti e non, sciroppi, chewing gum, ecc.) ed i diversi alimenti funzionali (pane, pasta, crakers, pizze focacce, biscotti, spremute, succhi, soft drinks, latte e derivati, miele, burro e margarine, condimenti vari, maionesi, creme, ecc.) contenenti i complessi fibrolipoproteici e le composizioni sopracitate, che possono essere utilizzati per la loro somministrazione orale. The present invention also relates to the different species of galenic compositions (tablets, sugared almonds, candies, sachets, effervescent and non-effervescent wafers, syrups, chewing gum, etc.) and the various functional foods (bread, pasta, crackers, pizza, focaccia, biscuits, juices, juices, soft drinks, milk and derivatives, honey, butter and margarines, various condiments, mayonnaise, creams, etc.) containing the fibrolipoprotein complexes and the aforementioned compositions, which can be used for their oral administration.
Infine l'invenzione si riferisce ai possibili procedimenti non limitativi per la preparazione dei complessi fibrolipoproteici sopra descritti. Finally, the invention relates to the possible non-limiting processes for the preparation of the fibrolipoprotein complexes described above.
Esempio 1 Example 1
Complessi fibrolipoproteici composti da: Fibrolipoprotein complexes composed of:
a) 100 g di caseinfosfopeptidi contenenti Ca isolati da caseine di latte bovino; a) 100 g of Ca-containing caseinphosphopeptides isolated from bovine milk caseins;
b) 100 g di lecitine di soia commerciali contenenti il 40% di fosfatidilcoline, il 35% di fosfatidiletanolammina, il 18% di fosfatidilinositolo e quote minori di altri fosfolipidi; b) 100 g of commercial soy lecithins containing 40% phosphatidylcholine, 35% phosphatidylethanolamine, 18% phosphatidylinositol and minor amounts of other phospholipids;
c) 300 g di fibra di avena commerciale. c) 300 g of commercial oat fiber.
Le lecitine di soia sono disciolte in esano ed aggiunte ad un evaporatore rotante contenente microsfere di vetro di diametro 1-2 mm, il solvente è evaporato sotto vuoto a 25°C così da ottenere un film di monomeri fosfolipidici adesi alle microsfere di vetro. Una soluzione acquosa tamponata a pH fisiologico e contenente la fibra di avena è aggiunta alle microsfere ricoperte dai fosfolipidi monostratificati e sottoposta a blanda agitazione per 30 minuti a 25°C. The soy lecithins are dissolved in hexane and added to a rotary evaporator containing glass microspheres with a diameter of 1-2 mm, the solvent is evaporated under vacuum at 25 ° C so as to obtain a film of phospholipid monomers adhered to the glass microspheres. An aqueous solution buffered at physiological pH and containing oat fiber is added to the microspheres coated with monostratified phospholipids and subjected to gentle stirring for 30 minutes at 25 ° C.
La soluzione che si intorbidisce progressivamente per il formarsi dei complessi fibrolipidici viene addizionata dei caseinfosfopeptidi e poi centrifugata a 3000 xg per 5 minuti per separare nel sedimento le microsfere di vetro; il superatante così ottenuto è poi essiccato in polvere per spray-drying. Tale polvere costituisce il complesso fibrolipoproteico e può essere usata come tale sia per l'allestimento delle composizioni farmaceutiche (o dietetiche) sia per la preparazione dei diversi alimenti funzionali. The solution that gradually becomes cloudy due to the formation of fibrolipidic complexes is added with caseinphosphopeptides and then centrifuged at 3000 xg for 5 minutes to separate the glass microspheres in the sediment; the superatant thus obtained is then dried into a powder by spray-drying. This powder constitutes the fibrolipoprotein complex and can be used as such both for the preparation of the pharmaceutical (or dietetic) compositions and for the preparation of the various functional foods.
Esempio 2 Example 2
Complessi fibrolipoproteici composti da: Fibrolipoprotein complexes composed of:
a) 50 g di latto ferrina; a) 50 g of lacto ferrina;
b) 100 g di lecitina di soia commerciale contenenti il 40% di fosfatidilcolina, il 35% di fosfatidiletanolammina, il 18% di fosfatidilinositolo e quote minori di altri fosfolipidi; b) 100 g of commercial soy lecithin containing 40% phosphatidylcholine, 35% phosphatidylethanolamine, 18% phosphatidylinositol and minor amounts of other phospholipids;
c) 300 g di fibre di avena commerciale. c) 300 g of commercial oat fiber.
Le tre polveri sono miscelate a lungo .per agitazione meccanica e successivamente disciolte lentamente in una soluzione acquosa sotto forte agitazione. Al termine l'emulsione così ottenuta viene essiccata in polvere per spray-drying. Tale polvere costituisce il complesso fibrolipoproteico e può essere utilizzato come tale sia per l'allestimento elle composizioni farmaceutiche (o dietetiche) che per la preparazione dei diversi alimenti funzionali. The three powders are mixed for a long time by mechanical stirring and then slowly dissolved in an aqueous solution under strong stirring. At the end the emulsion thus obtained is dried into a powder by spray-drying. This powder constitutes the fibrolipoprotein complex and can be used as such both for the preparation of pharmaceutical (or dietetic) compositions and for the preparation of the various functional foods.
Esempio 3 Example 3
Complessi fibrolipoproteici composti da: Fibrolipoprotein complexes composed of:
a) 160 g di caseinfosfopeptidi contenenti Ca isolati da caseine di latte bovino; a) 160 g of Ca-containing caseinphosphopeptides isolated from bovine milk caseins;
b) 100 g di lecitine di uovo commerciali contenenti il 50% di fosfatidilcoline, oltre il 35% di fosfatidiletanolammina e quote minori di altri fosfolipidi; b) 100 g of commercial egg lecithins containing 50% phosphatidylcholine, more than 35% phosphatidylethanolamine and minor amounts of other phospholipids;
c) 200 g di fibre: 150 g di fibre di avena e 50 g di fructooligosaccaridi. c) 200 g of fibers: 150 g of oat fibers and 50 g of fructooligosaccharides.
I complessi fibrolipoproteici di queste tre componenti sono ottenuti come già descritto al precedente esempio 2. The fibrolipoprotein complexes of these three components are obtained as already described in the previous example 2.
Esempio 4 Example 4
Complessi fibrolipoproteici composti da: Fibrolipoprotein complexes composed of:
a) 10 g di glutatione; a) 10 g of glutathione;
b) 25 g di lisolecitine di soia ottenute per idrolisi di lecitine di composizione analoga a quella riportata nel precedente esempio 2, punto b); b) 25 g of soy lysolecithins obtained by hydrolysis of lecithins of a composition similar to that reported in the previous example 2, point b);
c) 165 g di fibre: 100 g di fibre di avena e 65 g di chitosano. c) 165 g of fiber: 100 g of oat fiber and 65 g of chitosan.
I complessi fibrolipoproteici di queste tre componenti sono ottenuti come già descritto al precedente esempio 2. The fibrolipoprotein complexes of these three components are obtained as already described in the previous example 2.
Claims (7)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT99MI002263 IT1314206B1 (en) | 1999-10-29 | 1999-10-29 | Fibrous liponutritional complexes useful as nutritional supplements consist of nutritional substances, a phospholipid and vegetable or animal fibers |
AT00974454T ATE293895T1 (en) | 1999-10-29 | 2000-10-25 | FIBROUS LIPO NUTRITIONAL COMPLEXES AND COMPOSITIONS CONTAINING SAME |
AU12754/01A AU1275401A (en) | 1999-10-29 | 2000-10-25 | Fibrous-liponutritional complexes and compositions containing them |
JP2001534254A JP2003521241A (en) | 1999-10-29 | 2000-10-25 | Fibrous-lipid nutritional composite and compositions containing it |
DE60019784T DE60019784D1 (en) | 1999-10-29 | 2000-10-25 | FIBROUS LIPO NUTRITION COMPLEXES AND COMPOSITIONS CONTAINING THEREOF |
PCT/EP2000/010500 WO2001032038A1 (en) | 1999-10-29 | 2000-10-25 | Fibrous-liponutritional complexes and compositions containing them |
EP00974454A EP1225814B1 (en) | 1999-10-29 | 2000-10-25 | Fibrous-liponutritional complexes and compositions containing them |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT99MI002263 IT1314206B1 (en) | 1999-10-29 | 1999-10-29 | Fibrous liponutritional complexes useful as nutritional supplements consist of nutritional substances, a phospholipid and vegetable or animal fibers |
Publications (3)
Publication Number | Publication Date |
---|---|
ITMI992263A0 ITMI992263A0 (en) | 1999-10-29 |
ITMI992263A1 true ITMI992263A1 (en) | 2001-04-29 |
IT1314206B1 IT1314206B1 (en) | 2002-12-06 |
Family
ID=11383870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT99MI002263 IT1314206B1 (en) | 1999-10-29 | 1999-10-29 | Fibrous liponutritional complexes useful as nutritional supplements consist of nutritional substances, a phospholipid and vegetable or animal fibers |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT1314206B1 (en) |
-
1999
- 1999-10-29 IT IT99MI002263 patent/IT1314206B1/en active
Also Published As
Publication number | Publication date |
---|---|
IT1314206B1 (en) | 2002-12-06 |
ITMI992263A0 (en) | 1999-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101038354B1 (en) | Nutritional compositions | |
Kumar et al. | Whey Proteins: A potential ingredient for food industry-A review | |
DE69930746T2 (en) | PREVENTIVE AND THERAPEUTIC FOOD SUPPLEMENT FOR CREATING / MAINTAINING A HEALTH PROTECTING MICROFLORA AND FOR STRENGTHENING THE IMMUNE SYSTEM | |
ES2488098T3 (en) | Hydrolyzed protein-polysaccharide complexes | |
ES2429311T3 (en) | Protein hydrolyzate compositions with enhanced CCK release capacity | |
US6340669B1 (en) | Lipoprotein complexes and compositions containing them | |
NO340945B1 (en) | Nutritionally complete breast milk substitute | |
AU2006239561B2 (en) | Peptides having a health benefit and compositions comprising them | |
EP2253324A1 (en) | Use of a casein-derived peptide and compositions thereof as antihypertensive | |
EP3355701A2 (en) | Liquid nutritional composition comprising micellar casein and hydrolysed whey protein | |
CA2949858A1 (en) | Potato based protein mixtures and nutritional compositions comprising potato protein | |
US20110263505A1 (en) | Whey Protein Hydrolysate Containing Tryptophan Peptide Consisting of Alpha Lactalbumin and the Use Thereof | |
EP1225814B1 (en) | Fibrous-liponutritional complexes and compositions containing them | |
AU2005332128B2 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
KR20060082015A (en) | Composition for strengthening bone derived from egg | |
EP3212211B1 (en) | Milk protein hydrolysate for use in the treatment of diarrhoea | |
US20200404957A1 (en) | Nutritional compositions containing milk-derived peptides and uses thereof | |
US6797290B2 (en) | Compositions for appetite control and related methods | |
ITMI992263A1 (en) | FIBROLIPOPROTEIC COMPLEXES AND COMPOSITIONS CONTAINING THEM | |
Ahn | Egg components | |
JPH10257867A (en) | Food for improving hypoalbuminaemia | |
ITMI20001622A1 (en) | FIBROLIPONUTRATIONAL COMPLEXES AND COMPOSITIONS CONTAINING THEM | |
ES2260500T3 (en) | MODIFIED MENTIONINE FOOD PRODUCTS AND PROCESSES FOR MANUFACTURING. | |
Sharma | Functional foods roundup | |
ITMI990114A1 (en) | LIPOPROTEIC COMPLEXES AND COMPOSITIONS CONTAINING THEM |